OSE Immunotherapeutics SA (EPA:OSE)
France flag France · Delayed Price · Currency is EUR
5.82
+0.21 (3.74%)
Apr 1, 2025, 3:43 PM CET

OSE Immunotherapeutics Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Operating Revenue
69.882.2318.326.3110.42
Upgrade
Other Revenue
13.56---0
Upgrade
Revenue
83.442.2318.326.3110.42
Upgrade
Revenue Growth (YoY)
3646.52%-87.83%-30.43%152.48%-59.85%
Upgrade
Gross Profit
83.442.2318.326.3110.42
Upgrade
Selling, General & Admin
6.535.966.598.54.7
Upgrade
Research & Development
30.4517.0926.8230.4922.31
Upgrade
Other Operating Expenses
-0.130.240.160.12
Upgrade
Operating Expenses
39.725.2136.7842.9329.41
Upgrade
Operating Income
43.73-22.99-18.48-16.63-18.99
Upgrade
Interest Expense
-5.6-2.2-1.37-0.84-0.27
Upgrade
Interest & Investment Income
1.70.340.020.010.01
Upgrade
Currency Exchange Gain (Loss)
--0.04-00.040
Upgrade
Other Non Operating Income (Expenses)
01.661.820.2-0
Upgrade
EBT Excluding Unusual Items
39.83-23.23-18.02-17.22-19.25
Upgrade
Gain (Loss) on Sale of Investments
-0-0-
Upgrade
Pretax Income
39.83-23.22-18.02-17.21-19.25
Upgrade
Income Tax Expense
2.39-0.22-0.26-0.36-2.69
Upgrade
Net Income
37.45-23-17.76-16.85-16.56
Upgrade
Net Income to Common
37.45-23-17.76-16.85-16.56
Upgrade
Shares Outstanding (Basic)
2220191816
Upgrade
Shares Outstanding (Diluted)
2520191816
Upgrade
Shares Change (YoY)
29.34%5.58%2.05%16.71%4.46%
Upgrade
EPS (Basic)
1.72-1.18-0.96-0.93-1.06
Upgrade
EPS (Diluted)
1.48-1.18-0.96-0.93-1.06
Upgrade
Free Cash Flow
48.36-19.78-18.53-10.39-19.76
Upgrade
Free Cash Flow Per Share
1.91-1.01-1.00-0.57-1.27
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
52.41%-1032.15%-100.96%-63.20%-182.25%
Upgrade
Profit Margin
44.88%-1032.91%-97.04%-64.05%-158.89%
Upgrade
Free Cash Flow Margin
57.97%-888.19%-101.22%-39.50%-189.65%
Upgrade
EBITDA
49.26-22.66-15.68-14.66-18.72
Upgrade
EBITDA Margin
59.03%--85.69%-55.71%-179.63%
Upgrade
D&A For EBITDA
5.520.322.81.970.27
Upgrade
EBIT
43.73-22.99-18.48-16.63-18.99
Upgrade
EBIT Margin
52.41%--100.96%-63.20%-182.25%
Upgrade
Effective Tax Rate
5.99%----
Upgrade
Revenue as Reported
83.442.2318.326.3110.43
Upgrade
Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.